UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph ALL) during imatinib treatment

Leukemia, 2003-09, Vol.17 (9), p.1700-1706

2003

Volltextzugriff (PDF)

A randomized multicenter open label phase ii study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chromosome-positive (Ph+/BCR-ABL+) acute lymphoblastic leukemia (ALL) (CSTI571ADE 10)

Annals of hematology, 2003-11, Vol.82 (11), p.716-720

2003

Volltextzugriff (PDF)

Early modifications of host cell gene expression induced by HIV-1

AIDS (London), 1998-04, Vol.12 (6), p.563-570

1998

Volltextzugriff (PDF)

Differential expression profiles of apoptosis-affecting genes in HIV-infected cell lines and patient T cells

AIDS (London), 1999-02, Vol.13 (2), p.167-175

1999

Volltextzugriff (PDF)

Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)

Blood, 2005-07, Vol.106 (2), p.458-463

2005

Volltextzugriff (PDF)

Long-term benzimidazole treatment of alveolar echinococcosis with hematogenic subcutaneous and bone dissemination

Medical microbiology and immunology, 2003-11, Vol.192 (4), p.193-195

2003

Volltextzugriff (PDF)

Knockdown of ERM family member moesin in host cells increases HIV type 1 replication

AIDS research and human retroviruses, 2011-12, Vol.27 (12), p.1317-1322

2011

Volltextzugriff (PDF)

Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl–positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571)

Blood, 2003-01, Vol.101 (1), p.85-90

2003

Volltextzugriff (PDF)

Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: Final results

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.5025-5025

2007

Volltextzugriff (PDF)

Randomized phase II trial of the multi-kinase inhibitor sorafenib versus interferon (IFN) in treatment-naïve patients with metastatic renal cell carcinoma (mRCC)

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.4501-4501

2006

Volltextzugriff (PDF)

Proliferative arrest and cell cycle regulation in CD8 +CD28 − versus CD8 +CD28 + T cells

Human immunology, 2002-11, Vol.63 (11), p.1000-1009

2002

Volltextzugriff (PDF)

Proliferative Arrest and Cell Cycle Regulation in CD8 super(+)CD28 super(-) Versus CD8 super(+)CD28 super(+) T Cells

Human immunology, 2002-11, Vol.63 (11), p.1000-1009

2002

Volltextzugriff (PDF)

Serial minimal residual disease during imatinib treatment

Leukemia, 2003-09, Vol.17 (9)

2003

Volltextzugriff (PDF)

Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment : Spotlight on imatinib as a model for signal transduction inhibitors

Leukemia, 2003, Vol.17 (9), p.1700-1706

2003

Volltextzugriff (PDF)

Methodologic and biological variability of quantitative real-time polymerase chain reaction analysis of Bcr-Abl expression in Philadelphia chromosome-positive acute lymphoblastic leukemia

Haematologica (Roma), 2003-09, Vol.88 (9), p.1074

2003

Volltextzugriff (PDF)

Early modification of host cell gene expression induced by HIV-1

AIDS (London), 1998-04, Vol.12 (6), p.563-570

1998

Volltextzugriff (PDF)

ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer

Annals of oncology, 2020-05, Vol.31 (5), p.609-618

2020

Volltextzugriff (PDF)

Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia

Blood, 2006-02, Vol.107 (3), p.1116-1123

2006

Volltextzugriff (PDF)

Effect of post-study immunotherapy (IO) on overall survival (OS) outcome in patients with metastatic (m) NSCLC treated with first-line durvalumab (D) vs chemotherapy (CT) in the phase III MYSTIC study

Annals of oncology, 2019-04, Vol.30, p.ii77-ii77

2019

Volltextzugriff (PDF)

P-304 RECORA - A national non-interventional study to assess efficacy and safety of regorafenib in patients with metastatic colorectal cancer (mCRC) after failure of standard therapy

Annals of oncology, 2015-06, Vol.26, p.iv89

2015

Volltextzugriff (PDF)

1491PPD-L1 expression in primary tumour vs metastatic samples in the phase III MYSTIC study in first-line metastatic (m) NSCLC

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

PD-L1 expression in primary tumour vs metastatic samples in the phase III MYSTIC study in first-line metastatic (m) NSCLC

Annals of oncology, 2019-10, Vol.30, p.v611

2019

Volltextzugriff (PDF)

1491P - PD-L1 expression in primary tumour vs metastatic samples in the phase III MYSTIC study in first-line metastatic (m) NSCLC

Annals of oncology, 2019-10, Vol.30, p.v611-v611

2019

Volltextzugriff (PDF)

Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs chemotherapy (CT) in Asian patients with metastatic NSCLC: Results from MYSTIC

Annals of oncology, 2019-11, Vol.30, p.ix157-ix158

2019

Volltextzugriff (PDF)

OA04.07 Mutations Associated with Sensitivity or Resistance to Immunotherapy in mNSCLC: Analysis from the MYSTIC Trial

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S217-S217

2019

Volltextzugriff (PDF)

1 – 25 von 37

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(35)

Publikationsform

Artikel
(37)

Sprache

Englisch
(37)

Erscheinungsjahr

n.n

Thema

Science & Technology
(18)
Life Sciences & Biomedicine
(17)
Humans
(15)
Biological And Medical Sciences
(14)
Medical Sciences
(11)
Hematology
(6)
Female
(5)
Fundamental And Applied Biological Sciences. Psychology
(5)
Immunology
(5)
Microbiology
(5)
Middle Aged
(5)
Pharmacology. Drug Treatments
(5)
Benzamides
(4)
Hematologic And Hematopoietic Diseases
(4)
Imatinib Mesylate
(4)
Infectious Diseases
(4)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(4)
Male
(4)
Adult
(3)
Aids/hiv
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph ALL) during imatinib treatment

Early modifications of host cell gene expression induced by HIV-1

Differential expression profiles of apoptosis-affecting genes in HIV-infected cell lines and patient T cells

Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)

Long-term benzimidazole treatment of alveolar echinococcosis with hematogenic subcutaneous and bone dissemination

Knockdown of ERM family member moesin in host cells increases HIV type 1 replication

Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl–positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571)

Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: Final results

Randomized phase II trial of the multi-kinase inhibitor sorafenib versus interferon (IFN) in treatment-naïve patients with metastatic renal cell carcinoma (mRCC)

Proliferative arrest and cell cycle regulation in CD8 +CD28 − versus CD8 +CD28 + T cells

Proliferative Arrest and Cell Cycle Regulation in CD8 super(+)CD28 super(-) Versus CD8 super(+)CD28 super(+) T Cells

Serial minimal residual disease during imatinib treatment

Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment : Spotlight on imatinib as a model for signal transduction inhibitors

Methodologic and biological variability of quantitative real-time polymerase chain reaction analysis of Bcr-Abl expression in Philadelphia chromosome-positive acute lymphoblastic leukemia

Early modification of host cell gene expression induced by HIV-1

ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer

Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia

Effect of post-study immunotherapy (IO) on overall survival (OS) outcome in patients with metastatic (m) NSCLC treated with first-line durvalumab (D) vs chemotherapy (CT) in the phase III MYSTIC study

P-304 RECORA - A national non-interventional study to assess efficacy and safety of regorafenib in patients with metastatic colorectal cancer (mCRC) after failure of standard therapy

1491PPD-L1 expression in primary tumour vs metastatic samples in the phase III MYSTIC study in first-line metastatic (m) NSCLC

PD-L1 expression in primary tumour vs metastatic samples in the phase III MYSTIC study in first-line metastatic (m) NSCLC

1491P - PD-L1 expression in primary tumour vs metastatic samples in the phase III MYSTIC study in first-line metastatic (m) NSCLC

Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs chemotherapy (CT) in Asian patients with metastatic NSCLC: Results from MYSTIC

OA04.07 Mutations Associated with Sensitivity or Resistance to Immunotherapy in mNSCLC: Analysis from the MYSTIC Trial

Suchergebnisse filtern